Baricitinib for Refractory Takayasu Arteritis

Summary

Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches. For TKA refractory to TNF-α, Baricitinib, a reversible inhibitor of Janus kinases (JAK) family members JKA1 and JAK2, represents a potential treatment option. This study aims to assess the efficacy and safety of Baricitinib in TKA refractory to TNF-α inhibitors.

Timeline

Start

2023-04-03

Primary completion

2023-12-23

Completion

2024-06-08

Publications

• Li J, Xia W, Ji H, Gong X, Dong Q, Wu Y, Wang L, Peng M, Liu J, Ma K, Yu Q, Cui X, Luo Y, Zhu W, Zhang S, Chen S, Li Y, Li Z, Liu T. Baricitinib for Takayasu arteritis refractory to TNF-alpha inhibitors: a multicentre, single-arm trial. Rheumatology (Oxford). 2025 Oct 1;64(10):5262-5268. doi: 10.1093/rheumatology/keaf286.

Drugs

Indications